Best of the Week
Most Popular
1. US Housing Market House Prices Bull Market Trend Current State - Nadeem_Walayat
2.Gold and Silver End of Week Technical, CoT and Fundamental Status - Gary_Tanashian
3.Stock Market Dow Trend Forecast - April Update - Nadeem_Walayat
4.When Will the Stock Market’s Rally Stop? - Troy_Bombardia
5.Russia and China Intend to Drain the West of Its Gold - MoneyMetals
6.BAIDU (BIDU) - Top 10 Artificial Intelligence Stocks Investing To Profit from AI Mega-trend - Nadeem_Walayat
7.Stop Feeding the Chinese Empire - ‘Belt and Road’ Trojan Horse - Richard_Mills
8.Stock Market US China Trade War Panic! Trend Forecast May 2019 Update - Nadeem_Walayat
9.US China Trade Impasse Threatens US Lithium, Rare Earth Imports - Richard_Mills
10.How to Invest in AI Stocks to Profit from the Machine Intelligence Mega-trend - Nadeem_Walayat
Last 7 days
Silver Long-Term Trend Analysis - 18th June 19
IBM - Watson Deep Learning - AI Stocks Investing - Video - 18th June 19
Investors are Confident, Bullish and Buying Stocks, but… - 18th June 19
Gold and Silver Reversals – Impossible Not to Notice - 18th June 19
S&P 500 Stuck at 2,900, Still No Clear Direction - 17th June 19
Is Boris set to be the next Conservation leader? - 17th June 19
Clock’s Ticking on Your Chance to Profit from the Yield Curve Inversion - 17th June 19
Stock Market Rally Faltering? - 17th June 19
Johnson Vs Gove Tory Leadership Contest Grudge Match Betfair Betting - 17th June 19
Nasdaq Stock Index Prediction System Is Telling Us A Very Different Story - 17th June 19
King Dollar Rides Higher Creating Pressures On Foreign Economies - 17th June 19
Land Rover Discovery Sport Tailgate Not Working Problems Fix (70) - 17th June 19
Stock Market Outlook: is the S&P today just like 2007 or 2016? - 17th June 19
US China War - Thucydides Trap and gold - 16th June 19
Gold Stocks Bull Upleg Mounting - 16th June 19
Gold Price Seasonal Trend Analysis - Video - 16th June 19
Fethiye Market Fruit, Veg, Spices and Turkish Delight Tourist Shopping - 16th June 19
US Dollar Gold Trend Analysis - 15th June 19
Gold Stocks “Launch” is in Line With Fundamentals - 15th June 19
The Rise of Silver and Major Economic Decline - 15th June 19
Fire Insurance Claims: What Are the Things a Fire Claim Adjuster Does? - 15th June 19
How To Find A Trustworthy Casino? - 15th June 19
Boris Johnson Vs Michael Gove Tory Leadership Grudge Match - Video - 14th June 19
Gold and Silver, Precious Metals: T-Minus 3 Seconds To Liftoff! - 14th June 19
Silver Investing Trend Analysis - Video - 14th June 19
The American Dream Is Alive and Well - in China - 14th June 19
Keeping the Online Gaming Industry in Line - 14th June 19
How Acquisitions Affect Global Stocks - 14th June 19
Please Don’t Buy the Dip in Nvidia or Other Chip Stocks - 14th June 19
A Big Thing in Investor Education is Explainer Videos - 14th June 19
IRAN - The Next American War - 13th June 19
Boris Johnson Vs Michael Gove Tory Leadership Grudge Match Contest - 13th June 19
Top Best VPN Services You Can Choose For Your iPhone - 13th June 19
Tory Leadership Contest Betting Markets Forecast - Betfair - 13th June 19
US Stock Market Setting Up A Pennant Formation - 13th June 19
Which Stocks Will Lead The Cannabis Rebound? - 13th June 19
The Privatization of US Indo-Pacific Vision - Project 2049, Armitage, Budget Ploys and Taiwan Nexus - 12th June 19
Gold Price Breaks to the Upside - 12th June 19
Top Publicly Traded Casino Company Stocks for 2019 - 12th June 19
Silver Investing Trend Analysis - 12th June 19
Why Blue-Chip Dividend Stocks Aren’t as Safe as You Think - 12th June 19
Technical Analysis Shows Aug/Sept Stock Market Top Pattern Should Form - 12th June 19
FTSE 100: A Top European Index - 12th June 19
Gold Surprise! - 11th June 19
How Forex Indicators are Getting Even More Attention in the Market? - 11th June 19
Stock Market Storm Clouds on the Horizon - 11th June 19
Is Your Financial Security Based On A Double Aberration? - 11th June 19
What If Stocks Are Wrong About Interest Rate Cuts? - 11th June 19
US House Prices Yield Curve, Debt, QE4EVER! - 11th June 19
Natural Gas Moves Into Basing Zone - 11th June 19
U.S. Dollar Stall is Good for Commodities - 11th June 19
Fed Running Out of Time and Conventional Weapons - 11th June 19
Trade Wars Propelling Stock Markets to New Highs - 11th June 19
Best Travel Bags for Summer Holidays 2019, Back Sling packs, water proof, money belt, tactical - 11th June 19
Betting on Next British Prime Minister Tory Leadership Betfair Markets Forecast - 10th June 19
How Can Stock Market Go Up When We’re Headed Towards a Recession? - 10th June 19
If You Invest in Dividend Stocks, Do This to Double Your Returns - 10th June 19
Reasons for the Success of the Dating Market - 10th June 19
Gold Price Trend Analysis - Video - 10th June 19
US Stock Markets Rally Hard – Could Another Big Upside Leg Begin? - 10th June 19
Stock Market Huge Cosmic Cluster Ahead: Buckle Up! - 10th June 19
Stock Market Higher To Go? - 10th June 19
The Gold Price Golden Neckline… - 10th June 19
Gold Price Seasonal Trend Analysis - 9th June 19
The Fed Stops Pretending - 9th June 19
Fed Rate Cuts Soon; Bitcoin Enthusiasts Join Wall Street in Bashing Gold - 9th June 19
1990s vs. 2010s - Which Expansion Will be Better for Gold? - 9th June 19
Gold Price Trend Analysis, MACD, Trend Channels, Support / Resistance - 8th June 19
Gold Surges Near Breakout - 8th June 19
Could Gold Rally Above $3750 Before December 2019? - 8th June 19
5 Big Lies About Precious Metals Investing Exposed - 8th June 19

Market Oracle FREE Newsletter

Gold Price Trend Forecast Summer 2019

How to Ride the Surge in Biotech Mergers & Acquisitions

Companies / BioTech May 16, 2012 - 09:57 AM GMT

By: Money_Morning


Best Financial Markets Analysis ArticleDon Miller writes: Innovations in biotechnology are evolving at the speed of light.

In fact, astonishing advancements in biotech have transformed the way we practice medicine. Leading-edge biotech products and breakthroughs are literally saving thousands of lives every day.

Needless to say, biotech stocks can be strong medicine for investors, too.

For instance, the Nasdaq Biotechnology Index rose 457% from the end of August 1998 to the end of February 2000. Going back even further to the early 1990s, biotech stocks have soared by 1,347%.

Think about it... for biotech investors every $10,000 invested turned into nearly $140,000.

The good news for investors is that after slumping during the recession, biotech stocks are making a comeback. In the first quarter of 2012 alone, the Nasdaq Biotech Index gained 18.2%

And conditions are setting up for even better gains in the future.

Here's why...

M&A Drives Biotech Stocks Higher
While many biotech companies are riding high on new drugs, the recent surge in biotech stocks largely reflects a slew of mergers and acquisitions (M&A).

More importantly, more deals are likely on the horizon.

In fact, 91% of industry executives believe pharma-biotech mergers will increase in the next 10 years, according to

You see, big pharmaceutical companies are losing their patents on lucrative blockbuster drugs and are about to lose billions of dollars in sales.

For instance, Pfizer Inc.'s (NYSE: PFE) cholesterol-lowering drug Lipitor earned the company a smooth $5 billion or so last year. And Bristol-Myers Squibb Co. (NYSE: BME) and Sanofi-Aventis SA (ADR NYSE: SNY) pocketed more than $6 billion in U.S. sales from the blood thinner Plavix.

However, both those patents have expired, opening the door for generic versions that could cost up to 80% less.

Fortunately for Big Pharma they're flush with cash, and the biotech sector is full of smaller biotech development companies with promising pipelines.

So instead of spending billions on years of research and testing to develop their own drugs, it only makes sense for big companies to swallow biotech companies with new products in advanced stages.

"The upside here is that large pharmaceuticals will continue to acquire these companies...They have tons of cash...which makes almost every publicly-traded biotech a target for someone," Josh Brown, a New York City-based investment advisor recently wrote.

The trend accelerated earlier this month when GlaxoSmithKline plc (NYSE: GSK) launched a hostile takeover for Human Genome Sciences (Nasdaq: HGSI), after HGSI rebuffed a $2.6 billion offer.

But large war chests also mean there's lots of competition to buy the best small companies with the most promising pipelines.

Reduce Guesswork with Biotech Stock ETFs
The current supply/demand squeeze sets up a perfect scenario for investors because it's likely to drive the price of acquisitions sky-high, according to Money Morning Executive Editor Bill Patalon, who spent years covering the biotech industry.

However, investing in biotech stocks requires not only an understanding of the company's finances, but also knowledge of the company's potential based on its products and technologies.

You can reduce some of the guesswork by using exchange-traded funds (ETFs), which give you exposure without betting the farm on a single company.

ETFs trade on major exchanges and expenses are generally lower than those of actively traded mutual funds.

Here are three biotech ETFs to consider:

•iShares Nasdaq Biotechnology Index ETF (Nasdaq: IBB): The "granddaddy" of biotech ETFs was established in 2001 and carries a market cap of nearly $1.8 billion, making it the largest in the category. IBB tracks the Nasdaq Biotechnology Index and focuses on big players like Amgen Inc.(Nasdaq: AMGN) andCelgene Corp. (Nasdaq CELG). Its expense ratio is 0.48%. One-year return is 28.4% and its year-to-date (YTD) return is nearly 17%.
•SPDR S&P Biotech ETF (NYSEArca: XBI): XBI holds 30 large and small biotech companies in equal weightings. That means smaller components have equal say in its overall performance. Accordingly, the fund got a nice boost after HGSI's stock jumped on the takeover bid. With a market cap of $518 million, its expense ratio is 0.35%. One-year return is over 26% and its YTD return is 18%.
•PowerShares Dynamic Biotechnology & Genome Portfolio ETF: (NYSEArca: PBE). This fund holds the usual large-caps like Amgen and Biogen Idec Inc. (Nasdaq: BIIB), but it also holds promising small companies including BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), and Seattle Genetics Inc. (Nasdaq: SGEN), which have drugs in late-stage testing. Admittedly, it's higher risk, but these companies could be appetizing targets for Big Pharma. With a market cap of $140 million, its expense ratio is 0.63%. It has a one-year return of over 8% and a year-to-date return of 12%.

[Editor's Note: Handicapping buyout targets is a tall order. But we've already done the hard work for you.

Best of all: We've identified three biotech firms that are likely on a lot of radar screens.

But because they're quality companies with substantial growth potential, they are stocks worth holding even if no deals materialize.

To find out how to get your copy of the new report "The Biotech Buyout Binge: Why These Three Stocks Could Double Your Money in the Next Three Months" - just click here.]

Source :

Money Morning/The Money Map Report

©2011 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email:

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules